Publication of 20-Year Outcomes of Oncotype DX GPS Test
Returning guest, Dr. Eric Klein, Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic discusses new 20-year outcomes from a development study of the Oncotype DX Genomic Prostate Score® (GPS) test that was recently published in JCO Precision Oncology (March 2021). The study highlights the role of the GPS test, the only genomic test for prostate cancer with 20-year outcomes, in assessing the risk of long-term distant metastases (DM) and prostate cancer-specific mortality (PCSM) for patients with localized prostate cancer.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis, and kidney. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.
Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic.
Dr. Klein received his medical degree from the University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
